lysophosphatidic acid has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, X; Pingali, SR; Qian, J; Su, P; Wang, Q; Wang, Z; Xian, M; Xiao, L; Xiong, W; Yang, M; Ye, L; Yi, Q; Zu, Y | 1 |
| Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J | 1 |
2 other study(ies) available for lysophosphatidic acid and Multiple Myeloma
| Article | Year |
|---|---|
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors.
Topics: Apoptosis; Humans; Lysophospholipids; Multiple Myeloma; Proteasome Inhibitors | 2022 |
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine | 2008 |